We have not been selected for the 2022 Medtech Asia-Pacific Medtechinnovator 2022 Road Tour Program. We were supposed to make a second selection by the end of June 2022, but we received an unselected notice on July 21, 2022.

The mail from Medtech Innovator said that we should be proud of being included in the first 51 selected items.

Because Medtech strategic partners and other stakeholders were interested in us, we were first selected and entered the pitch event.

Many other companies that were finally selected this year were not selected in the previous year, but they were selected through various efforts and re-support, and we have also informed that we can apply again for the 2023 program.

We will keep in touch with the judges and have been invited to MedTech Innovator LIVE, and they have asked us to attend the APAC medTech Forum Asia Pacific 2022 in Singapore from September 26-27.

They also keep in touch, share progress continuously, hope to meet events or in person, and look forward to hearing progress later.

As a short Pitch event, they did not fully understand our Anyfusion, so we were not selected for this final event, but we expect it to be a good opportunity next time if various efforts are accompanied to promote Anyfusion continuously.

As the FDA reviewer does not understand Anyfusion's mechanical mechanism well, he wants to know more about Anyfusion, and he wants to understand it clearly through the STeP process, if MedTech strategic partners and stakeholders understand Anyfusion directly through additional events, contacts, and information exchanges, we can be selected. We will not give up hope.

Thank you for giving us the next opportunity, and we will do our best for the next time. Thank you Paul and the judges for the mail.

PS: Next, we will announce the results of the Anyfusion usage plan and FDA consulting contract at Asan Medical Center in Seoul.